secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2024-09-27T23:59:59+00:00
Accession:  0000950170-24-109753
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema targets IND for KAT6 drug OP-3136 in Q4 2024; Phase 1/2 starts 2025
-------------------------------------------------------------------------

- Non-clinical data for OP-3136 (KAT6 inhibitor) to be presented at ENA symposium Oct 23-25, 2024.
- IND submission for OP-3136 anticipated in Q4 2024.
- Phase 1/2 clinical study for OP-3136 expected to begin in 2025.
- Potential Phase 3 trial OPERA-02 (palazestrant + ribociclib) initiation planned for 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000095017024109753/0000950170-24-109753-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000095017024109753/olma-20240927.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-109753

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer